Brought to you by:
Lead vascular surgeon on first use of Fiber Optic RealShape in US hails advance
Vascular surgeons at the University of Massachusetts became the first in the United States to carry out procedures using the breakthrough imaging technology Fiber Optic RealShape (FORS) last month, reporting a 75% decrease in fluoroscopy use after one of their…
‘Disproportionate decrease’: Vascular surgeons see buying power fall, study finds
Inflation-adjusted Medicare reimbursement rates for the 20 most common vascular surgical procedures decreased by more than 20% in the last decade, a new analysis found. The study, which looked the buying power of vascular surgeons, uncovered data showing an unadjusted…
Medical Device Regulation goes into effect across EU
The European Union (EU) Medical Device Regulation (MDR) takes effect from today (May 26). The Regulation revises quality and safety standards and the range of regulated devices and was first initiated in May 2017, with an initial three-year transition period…
Medtronic issues updated patient management recommendations on Valiant Navion recall
Medtronic has announced that it has sent physicians updated patient management recommendations related to its voluntary recall of the Valiant Navion thoracic stent graft on Feb. 17. The original recall notice included the recommendation for physicians to follow best clinical…
Boston Scientific recalls Vici SDS and Vici RDS venous stent systems following reports of stent migration
According to a medical device recall notice posted on the Food and Drug Administration (FDA) website, Boston Scientific has recalled its Vici venous stent system (Vici SDS) and Vici RDS venous stent system due to reported instances of stent migration.…
Former SAVS president David Rosenthal dies at 76
Renowned vascular surgeon David Rosenthal, MD, co-founder of the Atlanta Vascular Society and a former president of both the Southern Association for Vascular Society (SAVS) and the Georgia Vascular Society, has died. He was 76. Beginning practice in Atlanta in…
One-year results from PROMISE I study of LimFlow system in ‘no-option’ CLTI patients published
Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been published in the Journal of Vascular Surgery. Results showed sustained positive outcomes for both amputation-free survival and…
Candidates for 2021-22 SVS vice president revealed
The candidates in the running to be the next Society for Vascular Surgery (SVS) vice president—and a future SVS president—have been unveiled. They are William Shutze, MD, and Joseph Mills, MD, both of whom operate in Texas and who, respectively,…
ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices
Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky, MD, an interventional cardiologist at Beth Israel Deaconess Medical Center (BIDMC) in Boston, reported this conclusion…
ACC.21: VOYAGER PAD shows rivaroxaban ‘significantly’ reduced total ischemic events in PAD patients
Rivaroxaban combined with low-dose aspirin led to a significant reduction in the occurrence of total ischemic events in patients with symptomatic peripheral arterial disease (PAD) who underwent lower-extremity revascularization, according to researchers conducting the VOYAGER PAD trial. The findings were…